YahooAugust 12, 2026 at 10:05 AM NY23 days ago
Altimmune Q2 Earnings Call Highlights
Altimmune (NASDAQ:ALT) said it has initiated patient enrollment in its global Phase III PERFORMA trial of pemvidutide for metabolic dysfunction-associated steatohepatitis, or MASH, while advancing plans for later-stage development in alcohol use disorder, or AUD. Chairman and Chief Executive Office
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site — Yahoo
Companies in This Story
Related Stories
Jim Cramer Thinks This Struggling Stock Could See A “Big Earnings Acceleration”
Yahoo3 hours ago
Walmart, Target, and Kroger face growing retail crime issue
Yahoo3 hours ago
Cramer Says a Wave of 21 Year Olds on Robinhood Is the Only Reason This Market Has Not Cracked
Yahoo5 hours ago
Top Research Reports for Apple, Broadcom & Shell
Yahoo6 hours ago
Wall Street Has Cooled on Moderna After Its Stock Jumped Over 5X. But Does the mRNA Leader Have More Room to Run?
Yahoo6 hours ago